t
ImmuPharma PLC announced on 11 September 2025 the exercise of 2,500,000 warrants at 5p per share, generating £125,000. The company has allotted these new ordinary shares, which represent 0.50% of the enlarged issued share capital, and will apply for their admission to AIM around 16 September 2025. Following admission, ImmuPharma's total issued share capital will consist of 502,223,932 ordinary shares.
| Date | 11 Sept 2025 |
| Time | 07:00:08 |
| Category | Miscellaneous |
| ID | 8588Y |
ImmuPharma PLC
("ImmuPharma" or the "Company")
Exercise of Warrants; Total Voting Rights
ImmuPharma plc (LSE : IMM), the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announces that the Company has received notice of exercise of 2,500,000 warrants over New Ordinary Shares of 1p each ("Ordinary Shares") at an exercise price of 5p per share, for a consideration of £125,000.
The New Ordinary Shares have been allotted today and are issued credited as fully paid and will rank pari passu in all respects with the Company's existing issued ordinary shares.
An application will be made for the New Ordinary Shares to be admitted to trading on the AIM market ("Admission") of the London Stock Exchange. It is anticipated that Admission will occur on or around Tuesday 16 September 2025.
The New Ordinary Shares represent 0.50% of the Company's enlarged issued share capital.
For the purposes of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority ("DTR"), the Board of ImmuPharma hereby notifies the market that following Admission, the Company's total issued share capital will consist of 502,223,932 Ordinary Shares with a nominal value of 1p each.
This figure may be used by Shareholders as the denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the Company under the DTR.
Ends
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.